Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
With exclusive access to key industry decision makers and best-in-class proprietary data, Scrip empowers you to understand the news behind the news.
How it helps
Use Scrip’s focus on the strategic implications of global pharma news to fully understand what worldwide developments in the industry mean for your business.
With end-to-end coverage encompassing the whole of the drug discovery, development, and product life cycle value chain, Scrip delivers analysis, news and insights across multiple therapy areas and product types.
How it works
Scrip provides business-critical market and company intelligence from our global network of analysts, journalists and key opinion leaders. They cover companies across the industry, from biotech start-ups to multinational giants such as Pfizer, Sanofi and Shire, and report on fields including cardiovascular, diabetes, dermatology, influenza, and oncology.
Scrip gives you access to the latest licensing opportunities, partnership deals, R&D activity, market access insights and company developments. Your subscription also includes the Scrip 100 annual review, which tracks and analyzes the performance of over 600 companies and provides additional insights into pharma industry topics that impact your business.
Scrip
By Scrip Team 18 Jan 2022
More progress for vaccines and oral antivirals in Asia as South Korea issues an approval for Novavax's vaccine, Pfizer files for Japanese approval of Paxlovid, and SK bio progresses late-stage trials of its recombinant vaccine.
Scrip
By Joseph Haas 17 Jan 2022
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
Scrip
By Ian Haydock 17 Jan 2022
In this week's podcast edition of Five Must-Know Things: easy alliances rather than big deals the focus at JP Morgan; multiple company roundups from JPM; and Lilly braces for impact of US CMS decision on Aduhelm.
Scrip
By Scrip Team 17 Jan 2022
Scrip's Kevin Grogan joins Datamonitor's Pamela Spicer and Davinderpreet Mangat to discuss the skin disease landscape and whether atopic dermatitis is now where psoriasis was a decade ago as another wave of innovative products start to reach the market.
Scrip
By Alaric DeArment 10 Jan 2022
At the J.P. Morgan meeting, the company said its business development priorities have not changed, but it plans to prioritize licensing and small acquisitions rather than big ticket deals in 2022.
Scrip
By Ian Haydock 10 Jan 2022
In this week's podcast edition of Five Must-Know Things: new mRNA vaccine deal for Pfizer and BioNTech; court ruling helps Novartis’s Gilenya; first cut-price generic Paxlovid launched; breaking down BridgeBio’s Phase III failure; and a look at gene editing companies to watch at JP Morgan.
Scrip
By Alaric DeArment 05 Jan 2022
The companies’ third vaccine-development deal shows how COVID cash has also led mRNA-focused companies to beef up their organic pipelines amid talk of a merger wave.
Scrip
By Alex Shimmings 04 Jan 2022
The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking.
Scrip
By Andrew McConaghie 23 Dec 2021
MIG Capital’s Matthias Kromayer looks back at the huge success of its long-term backing of BioNTech and discusses the group’s next big life sciences investments, but warns that realism and hard work are needed to achieve another breakthrough.
Scrip
By Vibha Ravi 22 Dec 2021
Ocugen’s mutation-agnostic candidate for retinitis pigmentosa and leber congenital amaurosis is set for Phase I trials in the US. In this exclusive audio interview, founder and CEO Shankar Musunuri speaks to Scrip about seeking partners beyond CanSino Biologics for the candidate while stressing Bharat Biotech’s COVID-19 vaccine could hold promise against the Omicron variant.
Scrip
By Ian Haydock 01 Dec 2021
Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months.
Scrip
By Andrew McConaghie 29 Nov 2021
While news of a potentially highly transmissible new variant is causing alarm, Pfizer/BioNTech and Moderna are already pursuing a multi-pronged response to B.1.1.529.
Scrip
By Andrew McConaghie 29 Nov 2021
While news of a potentially highly transmissible new variant is causing alarm, Pfizer/BioNTech and Moderna are already pursuing a multi-pronged response to B.1.1.529.
Scrip
By Ian Haydock 28 Nov 2021
In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna’s co-founder shares tips on innovation.
Scrip
By Mandy Jackson 25 Nov 2021
Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.
Scrip
24 May 2022
Scrip
24 May 2022
Scrip
23 May 2022
Scrip
23 May 2022
Scrip
23 May 2022
Scrip
23 May 2022
Scrip
23 May 2022
Scrip
23 May 2022
Scrip
23 May 2022
Scrip
20 May 2022
Scrip
20 May 2022
Scrip
20 May 2022
Scrip
20 May 2022
Scrip
20 May 2022
Scrip
20 May 2022
New York, USA
Brenda specializes in
41+ years of experience
Washington DC, USA
Cathy specializes in
41+ years of experience
Washington DC, USA
Denise specializes in
40+ years of experience
Support the development and validation of your strategic plans and ensure commercial decisions are based on marketplace realities. Datamonitor Healthcare offers expert coverage of key diseases, treatments, companies, drugs, market access and market trends. Results from in-depth KOL and payer interviews and physician surveys provide a current understanding of patient segmentation, influences and preferences, prescribing trends, unmet needs, and more
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, Biomedtracker helps you stay on top of breaking events, the drugs pipeline, upcoming milestones, companies, and deals – and their impact on the markets you care about.
Looking for more products Product Finder
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
